{"id":12401,"date":"2022-11-02T09:22:30","date_gmt":"2022-11-02T08:22:30","guid":{"rendered":"https:\/\/zzzzsbg.rs\/?p=12401"},"modified":"2022-11-02T13:04:16","modified_gmt":"2022-11-02T12:04:16","slug":"%d0%b5%d0%bf%d0%b8%d0%b4%d0%b5%d0%bc%d0%b8%d0%be%d0%bb%d0%be%d1%88%d0%ba%d0%b0-%d1%81%d0%b8%d1%82%d1%83%d0%b0%d1%86%d0%b8%d1%98%d0%b0-%d0%b8%d0%bd%d1%84%d0%b5%d0%ba%d1%86%d0%b8%d1%98%d0%b5-covid-19","status":"publish","type":"post","link":"https:\/\/zzzzsbg.rs\/en\/%d0%b5%d0%bf%d0%b8%d0%b4%d0%b5%d0%bc%d0%b8%d0%be%d0%bb%d0%be%d1%88%d0%ba%d0%b0-%d1%81%d0%b8%d1%82%d1%83%d0%b0%d1%86%d0%b8%d1%98%d0%b0-%d0%b8%d0%bd%d1%84%d0%b5%d0%ba%d1%86%d0%b8%d1%98%d0%b5-covid-19\/","title":{"rendered":"(Latinica) EPIDEMIOLO\u0160KA SITUACIJA INFEKCIJE COVID 19 ME\u0110U STUDENTIMA UNIVERZITETA U BEOGRADU"},"content":{"rendered":"

Sorry, this entry is only available in Latinica<\/a> and \u040b\u0438\u0440\u0438\u043b\u0438\u0446\u0430<\/a>. For the sake of viewer convenience, the content is shown below in one of the available alternative languages. You may click one of the links to switch the site language to another available language.<\/p>

Izve\u0161taj o epidemiolo\u0161koj situaciji infekcije COVID 19<\/em> me\u0111u studentima BU koji su se javili na pregled lekarima u ZZZZ Studenata Beograd tokom prve \u010detiri nedel\u0458e \u0161kolske 2022\/23 godine i tokom prethodne 2 \u0161kolske godine.<\/span><\/p>\n

EPIDEMIOLO\u0160KA SITUACIJA INFEKCIJE <\/strong>COVID 19 <\/strong><\/span>ME\u0110U STUDENTIMA UNIVERZITETA U BEOGRADU <\/strong><\/span>U \u0160KOLSKOJ 2022\/2023 GODINI<\/strong><\/span><\/p>\n

U toku prve \u010detiri nedel\u0458e \u0161kolske 2022\/23 godine – u periodu od 0<\/strong>3<\/strong>.<\/strong>10<\/strong>.202<\/strong>2<\/strong>.<\/strong>god.<\/strong> do<\/strong> 30<\/strong>.<\/strong>1<\/strong>0.<\/strong>2022.<\/strong> god. 78<\/strong>9<\/strong> studen<\/strong>ata Univerziteta u Beogradu<\/strong> se testiralo na prisustvo virusa SARS CoV2<\/em> u ZZZZ Studenata Beograd, zbog tegoba koje su upu\u0107ivale na infekciju Kovid 19, a od ovog broja 76<\/strong> sudenta je dobilo pozitivan rezultat <\/strong>testa<\/strong> (<\/strong>9,6<\/strong>%).<\/strong><\/span><\/p>\n

Na slede\u0107oj tabeli prikazani su:<\/span><\/p>\n

broj uzetih Ag testova\/broj (i %) pozitivnih rezultata; broj uzetih PCR testova\/broj (i %) pozitivnih rezultata kao i broj studenata<\/u><\/strong> koji su uradili Ag <\/strong>ili <\/strong>PCR <\/strong>test<\/strong> u ZZZZ Studenata i broj <\/strong>(<\/strong>i%<\/strong>) <\/strong>studenata sa pozitivnim rezultatima<\/strong> po nedel\u0458ama:<\/span><\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n
\u0160kolska 2022\/2023 godina, po nedel\u0458ama<\/span><\/p>\n

 <\/td>\n

Broj uzetih Ag testova\/ broj i % pozitivnih rezul-tata Ag testova<\/span><\/td>\nBroj uzetih PCR testova\/ broj i % pozitivnih rezul-tata PCR testova<\/span><\/td>\nbroj studenata testiranih\u00a0 na SARSCoV2<\/span><\/td>\nbroj i % pozitivnih studenata<\/span><\/td>\n<\/tr>\n
03.10. \u2013 09.10. 2022.<\/span><\/td>\n166\/21+\u00a0 (12,7%)<\/span><\/td>\n34\/7+\u00a0\u00a0 (20,6%)<\/span><\/td>\n170<\/span><\/td>\n28 (16,5%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n

10.10. \u2013 16.10. 2022.<\/span><\/td>\n208\/16+\u00a0 (7,7%)<\/span><\/td>\n52\/1+\u00a0\u00a0 (1,9%)<\/span><\/td>\n211<\/span><\/td>\n17 (8,1%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n

17.10. \u2013 23.10. 2022.<\/span><\/td>\n226\/14+\u00a0 (6,2%)<\/span><\/td>\n43\/4+\u00a0\u00a0 (9,3%)<\/span><\/td>\n228<\/span><\/td>\n18 (7,9%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n

24.10. \u2013 30.10. 2022.<\/span><\/td>\n179\/10+\u00a0 (5,6%)<\/span><\/td>\n29\/3+\u00a0\u00a0 (10,3%)<\/span><\/td>\n180<\/span><\/td>\n13 (7,2%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n

 <\/p>\n

UKUPNO<\/span><\/p>\n

 <\/td>\n

 <\/p>\n

779\/61+ (7,8%)<\/span><\/td>\n

 <\/p>\n

158\/15+\u00a0 (9,5%)<\/span><\/td>\n

 <\/p>\n

789<\/span><\/td>\n

 <\/p>\n

76 (9,6%)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/span>U nastavku teksta se nalazi izve\u0161taj za \u0161kolsku 2021\/22 godinu:<\/span><\/p>\n

EPIDEMIOLO\u0160KA SITUACIJA INFEKCIJE <\/strong>COVID 19 <\/strong><\/span>ME\u0110U STUDENTIMA UNIVERZITETA U BEOGRADU\u00a0 <\/strong><\/span>U \u0160KOLSKOJ 2021\/2022 GODINI<\/strong><\/span><\/p>\n

Tokom \u0161kolske 2021\/22 godine – u periodu od 0<\/strong>4<\/strong>.<\/strong>10<\/strong>.2021.<\/strong>god.<\/strong> do<\/strong> 2<\/strong>.<\/strong>1<\/strong>0.<\/strong>2022.<\/strong> god. 12.477<\/strong>studen<\/strong>a<\/strong>ta Univerziteta u Beogradu<\/strong> se testiralo na prisustvo virusa SARS CoV2<\/em> u ZZZZ Studenata Beograd, zbog tegoba koje su upu\u0107ivale na infekciju Kovid 19, a od ovog broja 3.724 <\/strong>sudenata je dobilo\u00a0 pozitivan rezultat <\/strong>testa<\/strong> (29,9%).<\/strong><\/span><\/p>\n

Na slede\u0107oj tabeli prikazani su:<\/span><\/p>\n

broj uzetih Ag testova\/broj (i %) pozitivnih rezultata; broj uzetih PCR testova\/broj (i %) pozitivnih rezultata kao i broj studenata<\/u><\/strong> koji su uradili Ag <\/strong>ili <\/strong>PCR <\/strong>test<\/strong> u ZZZZ Studenata i broj <\/strong>(<\/strong>i%<\/strong>) <\/strong>studenata sa pozitivnim rezultatima<\/strong> po nedel\u0458ama:<\/span><\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u0160kolska 2021\/2022 godina, po nedel\u0458ama<\/span><\/p>\n

 <\/td>\n

Broj uzetih Ag testova\/ broj i % pozitivnih rezul-tata Ag testova<\/span><\/td>\nBroj uzetih PCR testova\/ broj i % pozitivnih rezul-tata PCR testova<\/span><\/td>\nbroj studenata testiranih\u00a0 na SARSCoV2<\/span><\/td>\nbroj i % pozitivnih studenata<\/span><\/td>\n<\/tr>\n
04.10. \u2013 10.10. 2021.<\/span><\/td>\n365\/134+\u00a0 (36,7%)<\/span><\/td>\n100\/10+\u00a0\u00a0 (10%)<\/span><\/td>\n376<\/span><\/td>\n144 (38,3%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n

11.10. \u2013 17.10. 2021.<\/span><\/td>\n355\/120+\u00a0 (33,8%)<\/span><\/td>\n60\/8+\u00a0\u00a0\u00a0\u00a0\u00a0 (13,3%)<\/span><\/td>\n362<\/span><\/td>\n128 (35,4%)<\/span><\/td>\n<\/tr>\n
18.10. \u2013 24.10. 2021.<\/span><\/td>\n416\/158+\u00a0 (38%)<\/span><\/td>\n92\/16+\u00a0\u00a0\u00a0\u00a0\u00a0 (17,4%)<\/span><\/td>\n422<\/span><\/td>\n174 (40,8%)<\/span><\/td>\n<\/tr>\n
25.10. \u2013 31.10. 2021.<\/span><\/td>\n454\/157+\u00a0 (34,6%)<\/span><\/td>\n109\/13+\u00a0\u00a0\u00a0 (11,9%)<\/span><\/td>\n459<\/span><\/td>\n170 (37,1%)<\/span><\/td>\n<\/tr>\n
1.11. \u2013 7.11. 2021.<\/span><\/td>\n355\/112+\u00a0 (31,5%)<\/span><\/td>\n92\/19+\u00a0\u00a0\u00a0\u00a0 (20,6%)<\/span><\/td>\n361<\/span><\/td>\n131 (36,3%)<\/span><\/td>\n<\/tr>\n
8.11. \u2013 14.11. 2021.<\/span><\/td>\n224\/50+ (22,3%)<\/span><\/td>\n80\/6+\u00a0\u00a0\u00a0\u00a0\u00a0 (7,5%)<\/span><\/td>\n245<\/span><\/td>\n56\u00a0 (22,9%)<\/span><\/td>\n<\/tr>\n
15.11. \u2013 21.11. 2021.<\/span><\/td>\n257\/52+ (20,2%)<\/span><\/td>\n78\/5+\u00a0\u00a0\u00a0\u00a0\u00a0 (6,4%)<\/span><\/td>\n265<\/span><\/td>\n57\u00a0 (21,5%)<\/span><\/td>\n<\/tr>\n
22.11. \u2013 28.11. 2021.<\/span><\/td>\n204\/37+ (18,1%)<\/span><\/td>\n37\/1+\u00a0\u00a0\u00a0\u00a0\u00a0 (2,7%)<\/span><\/td>\n210<\/span><\/td>\n38\u00a0 (18,1%)<\/span><\/td>\n<\/tr>\n
29.11. \u2013 05.12. 2021.<\/span><\/td>\n216\/19+ (8,8%)<\/span><\/td>\n39\/1+\u00a0\u00a0\u00a0\u00a0\u00a0 (2,5%)<\/span><\/td>\n220<\/span><\/td>\n20\u00a0 (9,1%)<\/span><\/td>\n<\/tr>\n
06.12. \u2013 12.12. 2021.<\/span><\/td>\n171\/19+ (11,1%)<\/span><\/td>\n36\/2+\u00a0\u00a0\u00a0\u00a0\u00a0 (5,5%)<\/span><\/td>\n176<\/span><\/td>\n21\u00a0 (11,9%)<\/span><\/td>\n<\/tr>\n
13.12. \u2013 19.12. 2021.<\/span><\/td>\n193\/18+ (9,3%)<\/span><\/td>\n66\/2+\u00a0\u00a0\u00a0\u00a0\u00a0 (3,1%)<\/span><\/td>\n199<\/span><\/td>\n20\u00a0\u00a0 (10 %)<\/span><\/td>\n<\/tr>\n
20.12. \u2013 26.12. 2021.<\/span><\/td>\n228\/18+ (7,9%)<\/span><\/td>\n45\/3+\u00a0\u00a0\u00a0\u00a0\u00a0 (6,7%)<\/span><\/td>\n231<\/span><\/td>\n21\u00a0\u00a0 (9,1 %)<\/span><\/td>\n<\/tr>\n
27.12.2021. \u2013 2.1. 2022.<\/span><\/td>\n249\/65+ (26,1%)<\/span><\/td>\n71\/14+\u00a0\u00a0\u00a0 (19,1%)<\/span><\/td>\n320<\/span><\/td>\n79\u00a0\u00a0 (24,7 %)<\/span><\/td>\n<\/tr>\n
03.1.2022. -09.1. 2022.<\/span><\/td>\n592\/297+ (50,2%)<\/span><\/td>\n143\/44+\u00a0 (30,8%)<\/span><\/td>\n609<\/span><\/td>\n341\u00a0 (56%)<\/span><\/td>\n<\/tr>\n
10.1.2022. -16.1. 2022.<\/span><\/td>\n738\/292+ (39,6%)<\/span><\/td>\n261\/87+\u00a0 (33,3%)<\/span><\/td>\n749<\/span><\/td>\n379\u00a0 (50,6%)<\/span><\/td>\n<\/tr>\n
17.1.2022. -23.1. 2022.<\/span><\/td>\n565\/235+ (41,6%)<\/span><\/td>\n200\/52+\u00a0 (26%)<\/span><\/td>\n569<\/span><\/td>\n287\u00a0 (50,4%)<\/span><\/td>\n<\/tr>\n
24.1.2022. -30.1. 2022.<\/span><\/td>\n403\/172+ (42,7%)<\/span><\/td>\n138\/34+\u00a0 (24,6%)<\/span><\/td>\n407<\/span><\/td>\n206\u00a0 (50,5%)<\/span><\/td>\n<\/tr>\n
31.1.2022. -06.2. 2022.<\/span><\/td>\n322\/129+ (40,1%)<\/span><\/td>\n122\/26+\u00a0 (21,3%)<\/span><\/td>\n337<\/span><\/td>\n155\u00a0 (46%)<\/span><\/td>\n<\/tr>\n
07.2.2022. -13.2. 2022.<\/span><\/td>\n281\/98+ (34,9%)<\/span><\/td>\n144\/33+\u00a0 (22,9%)<\/span><\/td>\n296<\/span><\/td>\n131\u00a0 (44,2%)<\/span><\/td>\n<\/tr>\n
14.2.2022. -20.2. 2022.<\/span><\/td>\n234\/56+ (24%)<\/span><\/td>\n96\/19+\u00a0 (19,8%)<\/span><\/td>\n237<\/span><\/td>\n\u00a075\u00a0 (31,6%)<\/span><\/td>\n<\/tr>\n
21.2.2022. -27.2. 2022.<\/span><\/td>\n190\/40+ (21%)<\/span><\/td>\n64\/9+\u00a0 (14,1%)<\/span><\/td>\n191<\/span><\/td>\n\u00a049\u00a0 (25,6%)<\/span><\/td>\n<\/tr>\n
28.2.2022. -6.3. 2022.<\/span><\/td>\n173\/31+ (17,9%)<\/span><\/td>\n42\/3+\u00a0 (7,1%)<\/span><\/td>\n175<\/span><\/td>\n\u00a034\u00a0 (19,4%)<\/span><\/td>\n<\/tr>\n
7.3.2022. -13.3. 2022.<\/span><\/td>\n228\/25+ (11%)<\/span><\/td>\n70\/7+\u00a0 (10%)<\/span><\/td>\n232<\/span><\/td>\n\u00a032\u00a0 (13,8%)<\/span><\/td>\n<\/tr>\n
14.3.2022. -20.3. 2022.<\/span><\/td>\n295\/39+ (13,2%)<\/span><\/td>\n115\/2+\u00a0 (1,7%)<\/span><\/td>\n305<\/span><\/td>\n\u00a041\u00a0 (13,4%)<\/span><\/td>\n<\/tr>\n
21.3.2022. -27.3. 2022.<\/span><\/td>\n327\/40+ (12,2%)<\/span><\/td>\n116\/7+\u00a0 (6%)<\/span><\/td>\n337<\/span><\/td>\n\u00a047\u00a0 (13,9%)<\/span><\/td>\n<\/tr>\n
28.3.2022. -03.4. 2022.<\/span><\/td>\n266\/33+ (12,4%)<\/span><\/td>\n78\/7+\u00a0 (6%)<\/span><\/td>\n272<\/span><\/td>\n\u00a040\u00a0 (14,7%)<\/span><\/td>\n<\/tr>\n
04.4.2022. -10.4. 2022.<\/span><\/td>\n217\/18+ (8,3%)<\/span><\/td>\n59\/2+\u00a0 (3,4%)<\/span><\/td>\n225<\/span><\/td>\n\u00a020\u00a0 (8,9%)<\/span><\/td>\n<\/tr>\n
11.4.2022. -17.4. 2022.<\/span><\/td>\n216\/19+ (8,8%)<\/span><\/td>\n61\/0+\u00a0 (0%)<\/span><\/td>\n221<\/span><\/td>\n\u00a019\u00a0 (8,6%)<\/span><\/td>\n<\/tr>\n
18.4.2022. -24.4. 2022.<\/span><\/td>\n119\/6+ (5%)<\/span><\/td>\n26\/2+\u00a0 (7,7%)<\/span><\/td>\n127<\/span><\/td>\n\u00a0\u00a0 8\u00a0 (6,3%)<\/span><\/td>\n<\/tr>\n
25.4.2022. -1.5. 2022.<\/span><\/td>\n108\/3+ (2,8%)<\/span><\/td>\n24\/0+\u00a0 (0%)<\/span><\/td>\n112<\/span><\/td>\n\u00a0\u00a0 3\u00a0 (2,7%)<\/span><\/td>\n<\/tr>\n
2.5.2022. -8.5. 2022.<\/span><\/td>\n136\/8+ (5,9%)<\/span><\/td>\n24\/0+\u00a0 (0%)<\/span><\/td>\n138<\/span><\/td>\n\u00a0\u00a0 8\u00a0 (5,8%)<\/span><\/td>\n<\/tr>\n
9.5.2022. -15.5. 2022.<\/span><\/td>\n170\/3+ (1,8%)<\/span><\/td>\n23\/0+\u00a0 (0%)<\/span><\/td>\n173<\/span><\/td>\n\u00a0\u00a0 3\u00a0 (1,7%)<\/span><\/td>\n<\/tr>\n
16.5.2022. -22.5. 2022.<\/span><\/td>\n133\/13+ (9,8%)<\/span><\/td>\n24\/0+\u00a0 (0%)<\/span><\/td>\n142<\/span><\/td>\n\u00a0\u00a0 13\u00a0 (9,1%)<\/span><\/td>\n<\/tr>\n
23.5.2022. -29.5. 2022.<\/span><\/td>\n129\/5+ (3,9%)<\/span><\/td>\n22\/0+\u00a0 (0%)<\/span><\/td>\n132<\/span><\/td>\n\u00a0\u00a0 5\u00a0 (3,8%)<\/span><\/td>\n<\/tr>\n
30.5.2022. -5.6. 2022.<\/span><\/td>\n119\/6+ (5%)<\/span><\/td>\n23\/1+\u00a0 (4,3%)<\/span><\/td>\n125<\/span><\/td>\n\u00a0\u00a0 7\u00a0 (5,6%)<\/span><\/td>\n<\/tr>\n
06.6.2022. -12.6. 2022.<\/span><\/td>\n102\/5+ (4,9%)<\/span><\/td>\n16\/0+\u00a0 (0%)<\/span><\/td>\n105<\/span><\/td>\n\u00a0\u00a0 5\u00a0 (4,8%)<\/span><\/td>\n<\/tr>\n
13.6.2022. -19.6. 2022.<\/span><\/td>\n95\/4+ (4,2%)<\/span><\/td>\n10\/1+\u00a0 (10%)<\/span><\/td>\n97<\/span><\/td>\n\u00a0\u00a0 5\u00a0 (5,1%)<\/span><\/td>\n<\/tr>\n
20.6.2022. -26.6. 2022.<\/span><\/td>\n118\/23+ (19,5%)<\/span><\/td>\n12\/2+\u00a0 (16,7%)<\/span><\/td>\n123<\/span><\/td>\n\u00a0\u00a0 25\u00a0 (20,3%)<\/span><\/td>\n<\/tr>\n
27.6.2022. -03.7. 2022.<\/span><\/td>\n128\/27+ (21,1%)<\/span><\/td>\n20\/5+\u00a0 (25%)<\/span><\/td>\n134<\/span><\/td>\n\u00a0\u00a0 32\u00a0 (23,8%)<\/span><\/td>\n<\/tr>\n
04.7.2022.-10.07.2022<\/span><\/td>\n151\/41+ (27,1%)<\/span><\/td>\n20\/6+\u00a0 (30%)<\/span><\/td>\n157<\/span><\/td>\n\u00a0\u00a047\u00a0\u00a0\u00a0 (29.9%)<\/span><\/td>\n<\/tr>\n
11.07.2022.-17.07.2022.<\/span><\/td>\n135\/37+ (27,4%)<\/span><\/td>\n35\/6+ (18,2%)<\/span><\/td>\n168<\/span><\/td>\n\u00a0 43 (25,6%)<\/span><\/td>\n<\/tr>\n
18.07.2022-24.07.2022.<\/span><\/td>\n173\/61+ (35,5%)<\/span><\/td>\n40\/10+ (25%)<\/span><\/td>\n213<\/span><\/td>\n\u00a0 71 (33,3%)<\/span><\/td>\n<\/tr>\n
25.07.2022-31.07.2022.<\/span><\/td>\n184\/78+ (42,3%)<\/span><\/td>\n33\/10+ (30,3%)<\/span><\/td>\n193<\/span><\/td>\n\u00a0 88 (45,6%)<\/span><\/td>\n<\/tr>\n
1.08.2022-07.08. 2022.<\/span><\/td>\n147\/38+ (25,8%)<\/span><\/td>\n23\/10+ (43,5%)<\/span><\/td>\n148<\/span><\/td>\n\u00a0 48 (32,4%)<\/span><\/td>\n<\/tr>\n
8.08.2022-14.08. 2022.<\/span><\/td>\n161\/56+ (34,8%)<\/span><\/td>\n30\/5+ (16,7%)<\/span><\/td>\n166<\/span><\/td>\n\u00a0 61 (36,7%)<\/span><\/td>\n<\/tr>\n
15.08.2022-21.08. 2022.<\/span><\/td>\n133\/42+ (31,6%)<\/span><\/td>\n37\/8+ (21,6%)<\/span><\/td>\n138<\/span><\/td>\n\u00a0 50 (36,2%)<\/span><\/td>\n<\/tr>\n
22.08.2022-28.08. 2022.<\/span><\/td>\n152\/43+ (28,3%)<\/span><\/td>\n38\/8+ (21%)<\/span><\/td>\n156<\/span><\/td>\n\u00a0 51 (32,7%)<\/span><\/td>\n<\/tr>\n
29.08.2022-04.09. 2022.<\/span><\/td>\n149\/40+ (26,8%)<\/span><\/td>\n45\/5+ (11,1%)<\/span><\/td>\n150<\/span><\/td>\n\u00a0 45 (30%)<\/span><\/td>\n<\/tr>\n
05.09.2022-11.09. 2022.<\/span><\/td>\n123\/14+ (11,4%)<\/span><\/td>\n43\/9+ (20,9%)<\/span><\/td>\n127<\/span><\/td>\n\u00a0 23 (18,1%)<\/span><\/td>\n<\/tr>\n
12.09.2022-18.09. 2022.<\/span><\/td>\n151\/18+ (11,9%)<\/span><\/td>\n27\/3+ (11,1%)<\/span><\/td>\n153<\/span><\/td>\n\u00a0 21 (13,7%)<\/span><\/td>\n<\/tr>\n
19.09.2022-25.09. 2022.<\/span><\/td>\n151\/28+ (18,5%)<\/span><\/td>\n30\/4+ (13,3%)<\/span><\/td>\n152<\/span><\/td>\n\u00a0 32 (21,1%)<\/span><\/td>\n<\/tr>\n
26.09.2022-2.10. 2022.<\/span><\/td>\n138\/25+ (18,1%)<\/span><\/td>\n22\/2+ (9,1%)<\/span><\/td>\n140<\/span><\/td>\n\u00a0 27 (19,3%)<\/span><\/td>\n<\/tr>\n
 <\/p>\n

UKUPNO<\/span><\/td>\n

 <\/p>\n

12.039\/3.107+ (25,8%)<\/span><\/td>\n

 <\/p>\n

3261\/529+ (16,2%)<\/span><\/td>\n

 <\/p>\n

12.477<\/span><\/td>\n

 <\/p>\n

3724 (29,9%)<\/span><\/p>\n

 <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

U nastavku teksta se nalazi izve\u0161taj za \u0161kolsku 2020\/21 godinu:<\/span><\/p>\n

\u00a0<\/strong><\/span><\/p>\n

EPIDEMIOLO\u0160KA SITUACIJA INFEKCIJE <\/strong>COVID 19<\/strong> ME\u0110U STUDENTIMA UNIVERZITETA U BEOGRADU\u00a0 <\/strong><\/span>U PERIODU 1.09.<\/strong>2020. <\/strong>\u2013 <\/strong>3<\/strong>.10<\/strong>.2021. GODINE<\/strong><\/span><\/p>\n

Od po\u010detka \u0161kolske 2020\/21 godine, u periodu od 01.09.2020.g. do 3.10.2021.g. 10.535 <\/strong>studen<\/strong>a<\/strong>t<\/strong>a<\/strong> Univerziteta u Beogradu <\/strong>uradilo je PCR i\/ili antigenski test na SARS CoV2 u ZZZZ Studenata Beograd, a od ovog broja 3.076<\/strong> studenata je dobilo pozitivan rezultat <\/strong>testa<\/strong> (29,19 %).<\/strong><\/span><\/p>\n

Na slede\u0107oj tabeli prikazan je broj <\/u><\/strong>testova<\/u><\/strong> kod <\/strong>studenata<\/strong> koji su od 1.09. do 22.11.2020.g. bili PCR testovi, a od 23.11.2020.g do 3.10.2021.g. Ag ili PCR testovi, uzorkovani u ZZZZ Studenata Beograd, kao i broj (i %)\u00a0studenata sa pozitivnim rezultatima briseva, po nedel\u0458ama:<\/span><\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0Period\u00a0 od 1.9.2020.godine po nedel\u0458ama i 2021.godina<\/span><\/td>\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 broj te<\/strong>stova<\/strong><\/span><\/td>\nbroj i % pozitivnih<\/span><\/td>\n<\/tr>\n
01. do 06. Septembar 2020.<\/span><\/td>\n14<\/strong><\/span><\/td>\n0<\/span><\/td>\n<\/tr>\n
07. do 13. Septembar<\/span><\/td>\n26<\/strong><\/span><\/td>\n1 (3,8%)<\/span><\/td>\n<\/tr>\n
14. do 20. Septembar<\/span><\/td>\n28<\/strong><\/span><\/td>\n2 (7,1%)<\/span><\/td>\n<\/tr>\n
21. do 27. Septembar<\/span><\/td>\n26<\/strong><\/span><\/td>\n5 (19,2)<\/span><\/td>\n<\/tr>\n
28. sept. Do 4.oktobar<\/span><\/td>\n40<\/strong><\/span><\/td>\n1<\/strong> (2,5%)<\/span><\/td>\n<\/tr>\n
05. do 11. Oktobar<\/span><\/td>\n37<\/strong><\/span><\/td>\n5<\/strong> (13,5%)<\/span><\/td>\n<\/tr>\n
12. do 18. Oktobar<\/span><\/td>\n56<\/strong><\/span><\/td>\n13<\/strong> (23,2%)<\/span><\/td>\n<\/tr>\n
19. do 25.oktobar\u00a0<\/span><\/td>\n99<\/strong><\/span><\/td>\n37<\/strong> (37,4%)<\/span><\/td>\n<\/tr>\n
26.10. do 1.novembar<\/span><\/td>\n154<\/strong><\/span><\/td>\n82<\/strong> (53,2%)<\/span><\/td>\n<\/tr>\n
2.do 8. novembar<\/span><\/td>\n220<\/strong><\/span><\/td>\n134<\/strong> (60,9%)<\/span><\/td>\n<\/tr>\n
9. do 15. novembar<\/span><\/td>\n261<\/strong><\/span><\/td>\n201<\/strong> (77,0%)<\/span><\/td>\n<\/tr>\n
16. do 22. novembar<\/span><\/td>\n277<\/strong><\/span><\/td>\n195<\/strong> (70,4%)<\/span><\/td>\n<\/tr>\n
23. do 29. novembar<\/span><\/td>\n416<\/strong><\/span><\/p>\n

292 antigenskih <\/em><\/span><\/p>\n

124 <\/em>PCR<\/em><\/span><\/td>\n

202 <\/strong>(48,6%)<\/span><\/p>\n

129 (44,2%) antigenskih<\/em><\/span><\/p>\n

73 (58,9) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

30.nov. do 6.decembra<\/span><\/td>\n323<\/strong><\/span><\/p>\n

197 antigenskih <\/em><\/span><\/p>\n

126 <\/em>PCR<\/em><\/span><\/td>\n

133 <\/strong>(41,2%)<\/span><\/p>\n

68 (34,5%) antigenskih <\/em><\/span><\/p>\n

65 (51,6)<\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

7. do 13. decembar<\/span><\/td>\n319<\/strong><\/span><\/p>\n

228<\/em> antigenskih <\/em><\/span><\/p>\n

91 <\/em>PCR<\/em><\/span><\/td>\n

10<\/strong>5<\/strong>\u00a0 <\/strong>(32,9%)<\/span><\/p>\n

71<\/em> (<\/em>31,1<\/em> %) antigenskih<\/em><\/span><\/p>\n

34\u00a0 (37,4) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

14. do 20. decembar<\/span><\/td>\n222<\/strong><\/span><\/p>\n

157 antigenskih <\/em><\/span><\/p>\n

65<\/em> PCR<\/em><\/span><\/td>\n

81 <\/strong>\u00a0<\/strong>(36,5%)<\/span><\/p>\n

53<\/em> (<\/em>33,7<\/em> %) antigenskih<\/em><\/span><\/p>\n

28<\/em>\u00a0 (<\/em>43<\/em>,<\/em>1<\/em>) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

21. do 27. decembar<\/span><\/td>\n2<\/strong>33<\/strong><\/span><\/p>\n

181 antigenskih <\/em><\/span><\/p>\n

5<\/em>2 <\/em>PCR<\/em><\/span><\/td>\n

57<\/strong> \u00a0<\/strong>(24,5%)<\/span><\/p>\n

44 (24<\/em>,<\/em>3 %) antigenskih<\/em><\/span><\/p>\n

13\u00a0 (25%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

28.12.2020. \u00a0do 3.1.2021.<\/span><\/td>\n144<\/strong><\/span><\/p>\n

99 antigenskih <\/em><\/span><\/p>\n

4<\/em>5<\/em> PCR<\/em><\/span><\/td>\n

33<\/strong> \u00a0<\/strong>(22,9%)<\/span><\/p>\n

22 (22<\/em>,<\/em>2 %) antigenskih<\/em><\/span><\/p>\n

11\u00a0 (24,4%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

04.01.2021. \u00a0do 10.1.2021.<\/span><\/td>\n1<\/strong>32<\/strong><\/span><\/p>\n

102<\/em> antigenskih <\/em><\/span><\/p>\n

25 PCR<\/em><\/span><\/td>\n

36<\/strong> \u00a0<\/strong>(27,3%)<\/span><\/p>\n

2<\/em>9<\/em> (2<\/em>8,4<\/em> %) antigenskih<\/em><\/span><\/p>\n

7<\/em>\u00a0 (2<\/em>8<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

11.01.2021. \u00a0do 17.1.2021.<\/span><\/td>\n1<\/strong>37<\/strong><\/span><\/p>\n

99 antigenskih <\/em><\/span><\/p>\n

38 PCR<\/em><\/span><\/td>\n

40 <\/strong>\u00a0<\/strong>(29,2%)<\/span><\/p>\n

28 (2<\/em>8,3<\/em> %) antigenskih<\/em><\/span><\/p>\n

12\u00a0 (<\/em>31,6<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

18.01.2021. \u00a0do 24.1.2021.<\/span><\/td>\n150<\/strong><\/span><\/p>\n

116<\/em> antigenskih <\/em><\/span><\/p>\n

34 PCR<\/em><\/span><\/td>\n

38 <\/strong>\u00a0<\/strong>(25,3%)<\/span><\/p>\n

36<\/em> (<\/em>31,03<\/em> %) antigenskih<\/em><\/span><\/p>\n

2\u00a0 (<\/em>5,9<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

25.01.2021. \u00a0do 31.01.2021<\/span><\/td>\n152<\/strong><\/span><\/p>\n

1<\/em>24 antigenskih <\/em><\/span><\/p>\n

28<\/em> PCR<\/em><\/span><\/td>\n

3<\/strong>0<\/strong> \u00a0<\/strong>(19,7%)<\/span><\/p>\n

29 (23,4 %) antigenskih<\/em><\/span><\/p>\n

1\u00a0 (3<\/em>,<\/em>6%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

01.02.2021. \u00a0do 07.02.2021<\/span><\/td>\n1<\/strong>6<\/strong>2<\/strong><\/span><\/p>\n

113<\/em> antigenskih <\/em><\/span><\/p>\n

49 PCR<\/em><\/span><\/td>\n

38 <\/strong>\u00a0<\/strong>(23,5%)<\/span><\/p>\n

33<\/em> (2<\/em>9<\/em>,<\/em>2<\/em> %) antigenskih<\/em><\/span><\/p>\n

5<\/em>\u00a0 (<\/em>10,2<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

08.02.2021. \u00a0do 14.02.2021<\/span><\/td>\n1<\/strong>47<\/strong><\/span><\/p>\n

125<\/em> antigenskih <\/em><\/span><\/p>\n

22 PCR<\/em><\/span><\/td>\n

40 <\/strong>\u00a0<\/strong>(27,2%)<\/span><\/p>\n

39<\/em> (<\/em>31<\/em>,<\/em>2<\/em> %) antigenskih<\/em><\/span><\/p>\n

1\u00a0 (<\/em>4,5<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

15.02.2021. \u00a0do 21.02.2021<\/span><\/td>\n160<\/strong><\/span><\/p>\n

1<\/em>41 antigenskih <\/em><\/span><\/p>\n

19<\/em> PCR<\/em><\/span><\/td>\n

64<\/strong> \u00a0<\/strong>(40%)<\/span><\/p>\n

55 (<\/em>3<\/em>9 %) antigenskih<\/em><\/span><\/p>\n

9\u00a0 (<\/em>4<\/em>7<\/em>,<\/em>4%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

22.02.2021. \u00a0do 28.02.2021<\/span><\/td>\n290<\/strong><\/span><\/p>\n

240 antigenskih <\/em><\/span><\/p>\n

50<\/em> PCR<\/em><\/span><\/td>\n

122 <\/strong>(42,1%)<\/span><\/p>\n

115 (47,9 %) antigenskih<\/em><\/span><\/p>\n

7\u00a0 (14%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

01.03.2021. \u00a0do 07.03.2021<\/span><\/td>\n347<\/strong><\/span><\/p>\n

24<\/em>9<\/em> antigenskih <\/em><\/span><\/p>\n

98 PCR<\/em><\/span><\/td>\n

1<\/strong>39<\/strong> (40,1%)<\/span><\/p>\n

1<\/em>20<\/em> (4<\/em>8<\/em>,<\/em>2<\/em> %) antigenskih<\/em><\/span><\/p>\n

19 (1<\/em>9,4<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

08.03.2021. \u00a0do 14.03.2021<\/span><\/td>\n328<\/strong><\/span><\/p>\n

2<\/em>76<\/em> antigenskih <\/em><\/span><\/p>\n

52 PCR<\/em><\/span><\/td>\n

122 <\/strong>(37,2%)<\/span><\/p>\n

111 (40,<\/em>2<\/em> %) antigenskih<\/em><\/span><\/p>\n

1<\/em>1<\/em> ( <\/em>21,2<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

15.03.2021. \u00a0do 21.03.2021<\/span><\/td>\n270<\/strong><\/span><\/p>\n

2<\/em>14<\/em> antigenskih <\/em><\/span><\/p>\n

56 PCR<\/em><\/span><\/td>\n

99<\/strong> (36,7%)<\/span><\/p>\n

89<\/em> (4<\/em>1,6<\/em> %) antigenskih<\/em><\/span><\/p>\n

1<\/em>0<\/em> ( 17<\/em>,9<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

22.03.2021. \u00a0do 28.03.2021<\/span><\/td>\n249<\/strong><\/span><\/p>\n

2<\/em>00<\/em> antigenskih <\/em><\/span><\/p>\n

49 PCR<\/em><\/span><\/td>\n

83 <\/strong>(33,3%)<\/span><\/p>\n

71 (<\/em>35,5<\/em> %) antigenskih<\/em><\/span><\/p>\n

12 ( <\/em>24<\/em>,5<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

29.03.2021. \u00a0do 4.04.2021<\/span><\/td>\n227<\/strong><\/span><\/p>\n

182<\/em> antigenskih <\/em><\/span><\/p>\n

45 PCR<\/em><\/span><\/td>\n

8<\/strong>5<\/strong> (37,4%)<\/span><\/p>\n

8<\/em>1 (<\/em>44,5<\/em> %) antigenskih<\/em><\/span><\/p>\n

4<\/em> ( 8<\/em>,9<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

05.04.2021. \u00a0do 11.04.2021<\/span><\/td>\n212<\/strong><\/span><\/p>\n

164<\/em> antigenskih <\/em><\/span><\/p>\n

48\u00a0 PCR<\/em><\/span><\/td>\n

50<\/strong> (23,6%)<\/span><\/p>\n

45<\/em> (<\/em>27,4<\/em> %) antigenskih<\/em><\/span><\/p>\n

5 ( <\/em>10<\/em>,4<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

12.04.2021. \u00a0do 18.04.2021<\/span><\/td>\n198<\/strong><\/span><\/p>\n

147<\/em> antigenskih <\/em><\/span><\/p>\n

51\u00a0 PCR<\/em><\/span><\/td>\n

44<\/strong> (22,2%)<\/span><\/p>\n

39<\/em> (<\/em>26,5<\/em> %) antigenskih<\/em><\/span><\/p>\n

5 ( 9<\/em>,8<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

19.04.2021. \u00a0do 25.04.2021<\/span><\/td>\n186<\/strong><\/span><\/p>\n

14<\/em>8 antigenskih <\/em><\/span><\/p>\n

38<\/em>\u00a0 PCR<\/em><\/span><\/td>\n

27<\/strong> (14,5%)<\/span><\/p>\n

23 (15<\/em>,5<\/em> %) antigenskih<\/em><\/span><\/p>\n

4 ( 10,5%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

26.04.2021. \u00a0do 2.05.2021<\/span><\/td>\n131<\/strong><\/span><\/p>\n

98 antigenskih <\/em><\/span><\/p>\n

33<\/em>\u00a0 PCR<\/em><\/span><\/td>\n

26<\/strong> (19,8%)<\/span><\/p>\n

22 (22<\/em>,<\/em>4 %) antigenskih<\/em><\/span><\/p>\n

4 ( 12,1%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

03.05.2021. \u00a0do 09.05.2021<\/span><\/td>\n90<\/strong><\/span><\/p>\n

70<\/em> antigenskih<\/em><\/span><\/p>\n

20\u00a0 PCR<\/em><\/span><\/td>\n

11 (12.28%)<\/span><\/p>\n

10<\/em> (<\/em>14,3<\/em> %) antigenskih<\/em><\/span><\/p>\n

1<\/em> ( <\/em>5<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>10.<\/em>05.<\/em>2021. <\/em>\u00a0do <\/em>16<\/em>.05<\/em>.2021<\/em><\/span><\/td>\n153<\/strong><\/span><\/p>\n

124 antigenskih<\/em><\/span><\/p>\n

29\u00a0 PCR<\/em><\/span><\/td>\n

8 <\/strong>(<\/strong>5.22<\/strong>%)<\/strong><\/span><\/p>\n

8<\/em> (6,45%) antigenskih<\/em><\/span><\/p>\n

0 ( 0%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>17.<\/em>05.<\/em>2021. <\/em>\u00a0do 23.05<\/em>.2021<\/em><\/span><\/td>\n105<\/strong><\/span><\/p>\n

77<\/em> antigenskih<\/em><\/span><\/p>\n

28\u00a0 PCR<\/em><\/span><\/td>\n

4 <\/strong>(3<\/strong>.80<\/strong>%)<\/strong><\/span><\/p>\n

2 <\/em>(<\/em>2,59<\/em>%) antigenskih<\/em><\/span><\/p>\n

2<\/em> ( <\/em>7,14<\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>24.<\/em>05.<\/em>2021. <\/em>\u00a0do 3<\/em>0<\/em>.05<\/em>.2021<\/em><\/span><\/td>\n165<\/strong><\/span><\/p>\n

136 antigenskih<\/em><\/span><\/p>\n

29\u00a0 PCR<\/em><\/span><\/td>\n

2 <\/strong>(<\/strong>1,21<\/strong>%)<\/strong><\/span><\/p>\n

2 <\/em>(<\/em>1,47<\/em>%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*31<\/em>.<\/em>05.<\/em>2021. <\/em>\u00a0do 06.06<\/em>.2021<\/em><\/span><\/td>\n1<\/strong>7<\/strong>5<\/strong><\/span><\/p>\n

150 antigenskih<\/em><\/span><\/p>\n

25<\/em>\u00a0 PCR<\/em><\/span><\/td>\n

2 <\/strong>(<\/strong>1,1<\/strong>4%)<\/strong><\/span><\/p>\n

2 <\/em>(<\/em>1,<\/em>33%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*07<\/em>.<\/em>06.<\/em>2021. <\/em>\u00a0do 13.06<\/em>.2021<\/em><\/span><\/td>\n1<\/strong>59<\/strong><\/span><\/p>\n

136 antigenskih<\/em><\/span><\/p>\n

23<\/em>\u00a0 PCR<\/em><\/span><\/td>\n

6<\/strong> (3<\/strong>,<\/strong>77%)<\/strong><\/span><\/p>\n

6<\/em> (4<\/em>,<\/em>41%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>14.<\/em>06.<\/em>2021. <\/em>\u00a0do <\/em>20<\/em>.06<\/em>.2021<\/em><\/span><\/td>\n133<\/strong><\/span><\/p>\n

1<\/em>02<\/em> antigenskih<\/em><\/span><\/p>\n

3<\/em>1\u00a0 PCR<\/em><\/span><\/td>\n

1 <\/strong>(<\/strong>0,<\/strong>7<\/strong>5<\/strong>%)<\/strong><\/span><\/p>\n

1 <\/em>(<\/em>0,98<\/em>%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*21.06.<\/em>2021. <\/em>\u00a0do <\/em>27<\/em>.06<\/em>.2021<\/em><\/span><\/td>\n78<\/strong><\/span><\/p>\n

63<\/em> antigenskih<\/em><\/span><\/p>\n

15\u00a0 PCR<\/em><\/span><\/td>\n

0 <\/strong>(<\/strong>0<\/strong>%)<\/strong><\/span><\/p>\n

0 <\/em>(<\/em>0<\/em>%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*2<\/em>8<\/em>.06.<\/em>2021. <\/em>\u00a0do <\/em>0<\/em>4.0<\/em>7.2021<\/em><\/span><\/td>\n107<\/strong><\/span><\/p>\n

89 antigenskih<\/em><\/span><\/p>\n

18\u00a0 PCR<\/em><\/span><\/td>\n

1 <\/strong>(<\/strong>0,93<\/strong>%)<\/strong><\/span><\/p>\n

1 <\/em>(1,12%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>05<\/em>.0<\/em>7<\/em>.<\/em>2021. <\/em>\u00a0do <\/em>11<\/em>.0<\/em>7.2021<\/em><\/span><\/td>\n106<\/strong><\/span><\/p>\n

9<\/em>5<\/em> antigenskih<\/em><\/span><\/p>\n

11\u00a0 PCR<\/em><\/span><\/td>\n

6 (<\/strong>5,66<\/strong>%)<\/strong><\/span><\/p>\n

6 <\/em>(6,<\/em>31<\/em>%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*12.0<\/em>7<\/em>.<\/em>2021. <\/em>\u00a0do <\/em>1<\/em>8.0<\/em>7.2021<\/em><\/span><\/td>\n1<\/strong>40<\/strong><\/span><\/p>\n

113 antigenskih<\/em><\/span><\/p>\n

27<\/em>\u00a0 PCR<\/em><\/span><\/td>\n

8 (<\/strong>5,<\/strong>71%)<\/strong><\/span><\/p>\n

8<\/em> (7,07%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*1<\/em>9<\/em>.0<\/em>7<\/em>.<\/em>2021. <\/em>\u00a0do 25.0<\/em>7.2021<\/em><\/span><\/td>\n81<\/strong><\/span><\/p>\n

73<\/em> antigenskih<\/em><\/span><\/p>\n

8\u00a0 PCR<\/em><\/span><\/td>\n

2 <\/strong>(4<\/strong>,49<\/strong>%)<\/strong><\/span><\/p>\n

2 <\/em>(<\/em>2,<\/em>7<\/em>3<\/em>%) antigenskih<\/em><\/span><\/p>\n

0 ( <\/em>0 <\/em>%) <\/em>PCR<\/em><\/span><\/td>\n<\/tr>\n

*<\/em>26<\/em>.0<\/em>7<\/em>.<\/em>2021. <\/em>\u00a0do <\/em>1<\/em>.0<\/em>8.2021<\/em><\/span><\/td>\n123<\/em><\/strong><\/span><\/p>\n

111 antigenskih <\/em><\/span><\/p>\n

12 PCR<\/em><\/span><\/td>\n

14 (11,38%)<\/em><\/strong><\/span><\/p>\n

13 (11,71%) antigenskih<\/em><\/span><\/p>\n

1 (8,33) PCR<\/em><\/span><\/td>\n<\/tr>\n

*02.08.2021. <\/em>do 08.08.2021.<\/em><\/span><\/td>\n163<\/em><\/strong><\/span><\/p>\n

125 <\/em>antigenskih<\/em><\/span><\/p>\n

38 PCR<\/em><\/span><\/td>\n

13 (7,98%)<\/em><\/strong><\/span><\/p>\n

11 (8,8%) antigenskih<\/em><\/span><\/p>\n

2 (5,26%) PCR<\/em><\/span><\/td>\n<\/tr>\n

*09.08.2021. do 15.08.2021.<\/em><\/span><\/td>\n166<\/em><\/strong><\/span><\/p>\n

141 antigenskih<\/em><\/span><\/p>\n

25 PCR<\/em><\/span><\/td>\n

25 (15,06%)<\/em><\/strong><\/span><\/p>\n

24 (17,02%)<\/em><\/strong><\/span><\/p>\n

1 (4%)<\/em><\/strong><\/span><\/td>\n<\/tr>\n

16.08.2021. do 22.08.2021.<\/em><\/span><\/td>\n226<\/em><\/strong><\/span><\/p>\n

182 antigenskih<\/em><\/span><\/p>\n

44 PCR<\/em><\/span><\/td>\n

40 (17,69%)<\/em><\/strong><\/span><\/p>\n

38 (20,87%)<\/em><\/strong><\/span><\/p>\n

2 (2,27%)<\/em><\/strong><\/span><\/td>\n<\/tr>\n

23.08.2021. do 29.08.2021.<\/em><\/span><\/td>\n227<\/em><\/strong><\/span><\/p>\n

194 antigenskih<\/em><\/span><\/p>\n

33 PCR<\/em><\/span><\/td>\n

47 (20,7%)<\/em><\/strong><\/span><\/p>\n

39 (20,1%)<\/em><\/span><\/p>\n

8 (24,24%)<\/em><\/span><\/td>\n<\/tr>\n

30.08.2021. do 05.09.2021.<\/em><\/span><\/td>\n295<\/em><\/strong><\/span><\/p>\n

243 antigenskih<\/em><\/span><\/p>\n

52 PCR<\/em><\/span><\/td>\n

69 (23,4%)<\/em><\/strong><\/span><\/p>\n

59 (24,3%)<\/em><\/span><\/p>\n

10 (19,3%)<\/em><\/span><\/td>\n<\/tr>\n

6.09.2021. do 12.09.2021.<\/em><\/span><\/td>\n381<\/em><\/strong><\/span><\/p>\n

313 antigenskih<\/em><\/span><\/p>\n

68 PCR<\/em><\/span><\/td>\n

103 (27%)<\/em><\/strong><\/span><\/p>\n

90 (28,7%)<\/em><\/span><\/p>\n

13 (19,1%)<\/em><\/span><\/td>\n<\/tr>\n

13.09.2021. do 19.09.2021.<\/em><\/span><\/td>\n362<\/em><\/strong><\/span><\/p>\n

289 antigenskih<\/em><\/span><\/p>\n

73 PCR<\/em><\/span><\/td>\n

116 (32,04%)<\/em><\/strong><\/span><\/p>\n

107 (37,02%)<\/em><\/span><\/p>\n

9 (12,32%)<\/em><\/span><\/td>\n<\/tr>\n

20.09.2021. do 26.09.2021.<\/em><\/span><\/td>\n336<\/em><\/strong><\/span><\/p>\n

265 antigenskih<\/em><\/span><\/p>\n

71 PCR<\/em><\/span><\/td>\n

102 (30,35%)<\/em><\/strong><\/span><\/p>\n

93 (35,09%)<\/em><\/span><\/p>\n

9 (12,67%)<\/em><\/span><\/td>\n<\/tr>\n

27.09.2021. do 03.10.2021.<\/em><\/span><\/td>\n396<\/em><\/strong><\/span><\/p>\n

326 antigenskih<\/em><\/span><\/p>\n

70 PCR<\/em><\/span><\/td>\n

115 (29,04%)<\/em><\/strong><\/span><\/p>\n

83 (29,75%)<\/em><\/span><\/p>\n

17 (24,28%)<\/em><\/span><\/td>\n<\/tr>\n

 <\/p>\n

UKUPNO<\/strong><\/span><\/td>\n

7.309 <\/em>Ag<\/em><\/span><\/p>\n

3.226 <\/em>PCR<\/em><\/span><\/p>\n

10.535<\/strong><\/span><\/td>\n

1.968<\/em>\u00a0 (<\/em>26,92 <\/em>%) Ag <\/em><\/span><\/p>\n

1.093 <\/em>(3<\/em>3<\/em>,<\/em>88 <\/em>%) PCR<\/em><\/span><\/p>\n

3.076<\/strong> (29,19 %)<\/strong><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*u periodu od 10. maja 2021. do polovine avgusta 2021.g <\/em><\/strong>\u00a0jedan broj Ag testova se uzimao stranim studentima koji sti\u017eu u R Srbiju u okviru programa Ministarsta prosvete \u201eSvet u Srbiji\u201c i stanuju u kolektivnom sme\u0161taju (na Avali), kao i studentima kojima je bris neophodan za poha\u0111anje prakti\u010dne nastave na fakultetima<\/em>, <\/em>ispitima i sl.\u00a0 Iz tog razloga procenat pozitivnih studenaa u odnosu na broj testiranih u nedel\u0458ama posle 10. maja 2021.godine (do 15.08)<\/em> delimi\u010dno se mo\u017ee upore\u0111ivati sa podacima pre i posle ovih datuma, kada su brisevi uzimani iskl\u0458u\u010divo studentima koji\u00a0 su imali tegobe koje upu\u0107uju na infekciju <\/em>Covid 19<\/em>.<\/em><\/span><\/p>","protected":false},"excerpt":{"rendered":"

Sorry, this entry is only available in Latinica and \u040b\u0438\u0440\u0438\u043b\u0438\u0446\u0430. For the sake of viewer convenience, the content is shown below in one of the available alternative languages. You may click one of the links

Detaljnije...<\/span><\/a><\/p><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,9],"tags":[],"class_list":["post-12401","post","type-post","status-publish","format-standard","hentry","category-covid-19-aktuelne-informacije","category-aktuelnosti"],"_links":{"self":[{"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/posts\/12401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/comments?post=12401"}],"version-history":[{"count":0,"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/posts\/12401\/revisions"}],"wp:attachment":[{"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/media?parent=12401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/categories?post=12401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zzzzsbg.rs\/en\/wp-json\/wp\/v2\/tags?post=12401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}